CoChat

ATP11B mediates platinum resistance in ovarian cancer

Open access
Moreno-Smith, Myrthala, Halder, J.B., Meltzer, Paul S., Gonda, Tamas A., Mangala, Lingegowda S., Rupaimoole, Rajesha, Lu, Chunhua, Nagaraja, Archana S., Gharpure, Kshipra M., Kang, Yu, Rodriguez-Aguayo, Cristian, Vivas-Mejia, Pablo E., Zand, Behrouz, Schmandt, Rosemarie, Wang, Hua, Langley, Robert R., Jennings, Nicholas B., Ivan, Cristina, Coffin, Jeremy E., Armaiz, Guillermo N., Bottsford-Miller, Justin, Kim, Sang Bae, Halleck, Margaret S., Hendrix, Mary J.C., Bornman, William, Bar-Eli, Menashe, Lee, Ju-Seog, Siddik, Zahid H., Lopez-Berestein, Gabriel, Sood, Anil K. · 2018 · Journal of Clinical Investigation
Cited by 59

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Platinum compounds display clinical activity against a wide variety of solid tumors; however, resistance to these agents is a major limitation in cancer therapy. Reduced platinum uptake and increased platinum export are examples of resistance mechanisms that limit the extent of DNA damage. Here, we report the discovery and characterization of the role of ATP11B, a P-type ATPase membrane protein, in cisplatin resistance. We found that ATP11B expression was correlated with higher tumor grade in human ovarian cancer samples and with cisplatin resistance in human ovarian cancer cell lines. ATP11B gene silencing restored the sensitivity of ovarian cancer cell lines to cisplatin in vitro. Combined therapy of cisplatin and ATP11B-targeted siRNA significantly decreased cancer growth in mice bearing ovarian tumors derived from cisplatin-sensitive and -resistant cells. In vitro mechanistic studies on cellular platinum content and cisplatin efflux kinetics indicated that ATP11B enhances the export of cisplatin from cells. The colocalization of ATP11B with fluorescent cisplatin and with vesicular trafficking proteins, such as syntaxin-6 (STX6) and vesicular-associated membrane protein 4 (VAMP4), strongly suggests that ATP11B contributes to secretory vesicular transport of cisplatin from Golgi to plasma membrane. In conclusion, inhibition of ATP11B expression could serve as a therapeutic strategy to overcome cisplatin resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci122301

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 59

Metadata

Authors
Moreno-Smith, M., Halder, J. B., Meltzer, P. S., Gonda, T. A., Mangala, L. S., Rupaimoole, R., Lu, C., Nagaraja, A. S., Gharpure, K. M., Kang, Y., Rodriguez-Aguayo, C., Vivas-Mejia, P. E., Zand, B., Schmandt, R., Wang, H., Langley, R. R., Jennings, N. B., Ivan, C., Coffin, J. E., Armaiz, G. N., Bottsford-Miller, J., Kim, S. B., Halleck, M. S., Hendrix, M. J. C., Bornman, W., Bar-Eli, M., Lee, J.-S., Siddik, Z. H., Lopez-Berestein, G., & Sood, A. K.
Venue
Journal of Clinical Investigation
Published
2018-05-29
Volume
128
Issue
7
Pages
3199-3199
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2022447256
Cited by
59
References
2
FWCI
1.01
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.